Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease

  • Francisco J. Diaz-Corrales
  • Salome Sanz-Viedma
  • David Garcia-Solis
  • Teresa Escobar-Delgado
  • Pablo MirEmail author
Original Article



To determine clinical predictors and accuracy of 123I-FP-CIT SPECT imaging in the differentiation of drug-induced parkinsonism (DIP) and Parkinson’s disease (PD).


Several clinical features and 123I-FP-CIT SPECT images in 32 patients with DIP, 25 patients with PD unmasked by antidopaminergic drugs (PDu) and 22 patients with PD without a previous history of antidopaminergic treatment (PDc) were retrospectively evaluated.


DIP and PD shared all clinical features except symmetry of parkinsonian signs which was more frequently observed in patients with DIP (46.9%) than in patients with PDu (16.0%, p<0.05) or PDc (4.5%, p<0.01). Qualitatively 123I-FP-CIT SPECT images were normal in 29 patients with DIP (90.6%) and abnormal in all patients with PD, and this imaging technique showed high levels of accuracy.


DIP and PD are difficult to differentiate based on clinical signs. The precision of clinical diagnosis could be reliably enhanced by 123I-FP-CIT SPECT imaging.


Drug-induced parkinsonism Parkinson’s disease 123I-FP-CIT SPECT imaging Dopamine transporter 



This study was supported by grants from the Ministerio de Educación y Ciencia de España (SAF2007-60700), the Consejería de Innovación, Ciencia y Empresa de la Junta de Andalucia (CVI-02526), and the Consejería de Salud de la Junta de Andalucia (PI-0377/2007). Francisco J. Díaz Corrales was supported by a fellowship from the Fundación Carolina/BBVA. The authors thank Javier Luis Simón and Juan Manuel Praena Fernández for their valuable statistical advice. We thank Asad Nawaz for English grammar corrections.


  1. 1.
    Alvarez MV, Evidente VG. Understanding drug-induced parkinsonism. Separating pearls from oysters. Neurology 2008;70:e32–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006;74:2046–54.PubMedGoogle Scholar
  3. 3.
    Hirose G. Drug induced parkinsonism: a review. J Neurol 2006;253(Suppl 3):22–24.Google Scholar
  4. 4.
    Van Gerpen JA. Drug-induced parkinsonism. Neurologist 2002;8:363–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 2006;21:510–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Tolosa E, Coelho M, Gallardo M. DAT Imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl 7):S28–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229–38.CrossRefPubMedGoogle Scholar
  8. 8.
    Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999;56:33–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Marti Masso JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolución histórica de los fármacos implicados. Neurologia 1996;11:10–5.PubMedGoogle Scholar
  12. 12.
    Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2007;23:401–4.CrossRefGoogle Scholar
  13. 13.
    Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054–60.PubMedGoogle Scholar
  14. 14.
    Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001;108:1299–308.CrossRefPubMedGoogle Scholar
  16. 16.
    Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004;45:1688–93.PubMedGoogle Scholar
  17. 17.
    Sayed IS, Zakaria A, Nik N. Comparison of Chang’s with Sorenson’s attenuation correction method by varying linear attenuation coefficient values in Tc-99m SPECT imaging. In: Gao X, et al., editors. Medical imaging and informatics. Berlin: Springer-Verlag; 2008. p. 216–22.CrossRefGoogle Scholar
  18. 18.
    Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. Neurol Sci 2006;27:397–401.CrossRefPubMedGoogle Scholar
  21. 21.
    Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJA, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Seibyl JP, Marek KL, Quilan D. Decreased single-photon emission computed tomography [123I]beta-CIT striatal uptake correlated with symptom severity in Parkinson’s disease. Ann Neurol 1995;38:589–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Leo RJ. Movement disorders associated with serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449–54.PubMedGoogle Scholar
  25. 25.
    Pina Latorre MA, Modrego PJ, Rodilla F, Catalán C, Calvo M. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther 2001;26:111–2.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Francisco J. Diaz-Corrales
    • 1
  • Salome Sanz-Viedma
    • 2
  • David Garcia-Solis
    • 2
    • 3
  • Teresa Escobar-Delgado
    • 1
  • Pablo Mir
    • 1
    • 3
    • 4
    Email author
  1. 1.Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de SevillaHospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevilleSpain
  2. 2.Unidad Diagnóstica de Medicina NuclearHospital Universitario Virgen del RocioSevilleSpain
  3. 3.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)SevilleSpain
  4. 4.Unidad de Trastornos del Movimiento. Servicio de NeurologíaHospital Universitario Virgen del RocíoSevilleSpain

Personalised recommendations